Anti-VEGF Antibody Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical formulations of anti-VEGF antibodies face challenges in maintaining high concentrations while minimizing aggregation and sub-visible particles, which can lead to immune responses and stability issues, particularly in ophthalmic applications where particulates can cause eye damage and regulatory standards must be met.
Innovation Solution
Aqueous pharmaceutical compositions comprising high concentrations of anti-VEGF antibodies, stabilized with sucrose, citrate or histidine buffers, and polysorbate 80, which maintain low aggregation and sub-visible particles, ensuring stability and biological activity for extended storage periods, particularly suitable for ophthalmic administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high concentration of anti-VEGF antibody is formulated, then small injection volume is achieved, but aggregation and sub-visible particles increase leading to reduced stability and safety
Solution Approach 1:
The patent systematically optimizes multiple formulation parameters including pH (6.5-7.5), ionic strength (50-200 mM NaCl), surfactant concentration (0.01-0.1% polysorbate 80), and excipient ratios to achieve stable high-concentration antibody formulations. This multi-parameter optimization resolves the contradiction by finding the precise parameter window where high concentration does not necessarily lead to aggregation
Solution Approach 2:
The patent introduces multiple intermediary substances including sucrose (2-10%), gelatin (0.1-1%), and polysorbate 80 (0.01-0.1%) that act as stabilizers and anti-aggregation agents. These intermediaries mediate between the high antibody concentration and the tendency to aggregate, preventing direct antibody-antibody interactions that would lead to precipitation and particulate formation
2Productivity
If high concentration of anti-VEGF antibody is formulated, then dosing efficiency is improved, but immune response and safety concerns increase due to aggregation
Solution Approach 1:
The patent optimizes formulation parameters to maintain antibody monomeric state at high concentrations, specifically controlling pH and ionic strength to prevent conformational changes that would trigger immune responses. This allows high dosing efficiency without the harmful effects of aggregation-induced immunogenicity
3Quantity of substance
If high concentration of protein is formulated, then solubility limits are exceeded, but aggregation and crystallization occur leading to cloudiness and turbidity
Solution Approach 1:
The patent employs sucrose and gelatin as intermediary substances that interact with the antibody surface, preventing direct antibody-antibody interactions that would lead to aggregation and crystallization. These intermediaries maintain solubility at high concentrations by occupying surface sites and preventing nucleation events
Solution Approach 2:
The patent carefully controls pH (6.5-7.5) and ionic strength to maintain the antibody in a conformational state that is soluble at high concentrations. By optimizing these parameters, the patent prevents the concentration-dependent aggregation and crystallization that would otherwise occur
4Quantity of substance
If high concentration formulation is prepared, then manufacturing complexity increases, but stability and particle control become unpredictable
Solution Approach 1:
The patent establishes specific parameter ranges (pH 6.5-7.5, NaCl 50-200 mM, polysorbate 80 0.01-0.1%, sucrose 2-10%) that provide predictable and reproducible high-concentration formulations. By defining these parameter windows, the patent reduces manufacturing complexity while maintaining stability and particle control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions achieve long-term stability and low aggregation, meeting regulatory standards for sub-visible particles, ensuring safety and efficacy in ophthalmic applications by maintaining biological activity and preventing cloudiness or crystallization.
Implementation Method 1
Aqueous pharmaceutical compositions comprising high concentrations of anti-VEGF antibodies, stabilized with sucrose
Implementation Method 2
stabilized with sucrose, citrate or histidine buffers, and polysorbate 80, which maintain low aggregation and sub-visible particles
Implementation Method 3
stabilized with sucrose, citrate or histidine buffers
Data Source
AI summary
The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.